Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Change in Receivables (2018 - 2025)

Historic Change in Receivables for ImmunoTech (AIM) over the last 6 years, with Q1 2025 value amounting to $19000.0.

  • ImmunoTech's Change in Receivables rose 10160.47% to $19000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $19000.0, marking a year-over-year increase of 10113.23%. This contributed to the annual value of -$1.2 million for FY2024, which is 14065.04% down from last year.
  • According to the latest figures from Q1 2025, ImmunoTech's Change in Receivables is $19000.0, which was up 10160.47% from -$3000.0 recorded in Q4 2024.
  • In the past 5 years, ImmunoTech's Change in Receivables registered a high of $1.2 million during Q4 2023, and its lowest value of -$1.7 million during Q2 2023.
  • Over the past 3 years, ImmunoTech's median Change in Receivables value was $0.0 (recorded in 2024), while the average stood at -$276500.0.
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 10025.34% in 2024, then soared by 10160.47% in 2025.
  • ImmunoTech's Change in Receivables (Quarter) stood at $1.2 million in 2023, then plummeted by 100.25% to -$3000.0 in 2024, then surged by 733.33% to $19000.0 in 2025.
  • Its last three reported values are $19000.0 in Q1 2025, -$3000.0 for Q4 2024, and $3000.0 during Q2 2024.